Statin use and cancer risk: an epidemiologic review (Q36508082)

14 August 2017

1 reference

title

Statin use and cancer risk: an epidemiologic review (English)

1 reference

14 August 2017

Jørgen H Olsen

2

0 references

author name string

Søren Friis

series ordinal

1

1 reference

14 August 2017

publication date

1 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

413-424

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Pleiotropic effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

The lipid and non-lipid effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Are statins a treatment option for multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Carcinogenicity of lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statins and cancer development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statin use, hyperlipidaemia, and the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statin use and the risk of breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statin use and cancer risk in the General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Cancer risk among statin users: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statins and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statins and prostate cancer risk: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

The potential of statins as part of anti-cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Therapy insight: Potential of statins for cancer chemoprevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Safety of statins: focus on clinical pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Non-lipid-related effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statins and risk of polyneuropathy: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Current perspectives on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Molecular Regulation of Cholesterol Biosynthesis: Implications in Carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Recent advances in the study of prenylated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lovastatin induces apoptosis in malignant mesothelioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21 in Human Prostate Carcinoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

ras p21 Isoprenylation inhibition induces flat colon tumors in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statins can inhibit proliferation of human breast cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lovastatin-induced apoptosis in human melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Studies in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Do statins cause cancer? A meta-analysis of large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Security and maximal tolerated doses of fluvastatin in pediatric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Interaction of cytosine arabinoside and lovastatin in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Statins and the Risk of Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lipid-Lowering Medication and Risk of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

Lipid-Lowering Drug Use and Breast Cancer in Older Women: A Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900600705532

10.1080/07357900600705532

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference